Safety and efficacy at 1 year after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide in patients with chronic hepatitis B and risk factors for TDF use

被引：0

作者：

Gane, E. ^{[1
]}

Seto, W. K. ^{[2
]}

Janssen, H. ^{[3
]}

Caruntu, F. A. ^{[4
]}

Kim, H. J. ^{[5
]}

Abdurakhmanov, D. ^{[6
]}

Nishiguchi, S. ^{[7
]}

Andrzej, H. ^{[8
]}

Bae, H. ^{[9
]}

Mo, S. ^{[10
]}

Suri, V. ^{[10
]}

Gaggar, A. ^{[10
]}

Flaherty, J. F. ^{[10
]}

Kao, J-H ^{[11
]}

Brunetto, M. ^{[12
]}

Buti Ferret, M. ^{[13
]}

机构：

[1] Auckland Clin Studies, Auckland, New Zealand

[2] Queen Mary Hosp, Hong Kong, Peoples R China

[3] Toronto Gen Hosp, Toronto, ON, Canada

[4] Natl Inst Infect Dis Matei Bals, Infect Dis, Bucharest, Romania

[5] Chung Ang Hosp, Seoul, South Korea

[6] Sechenov First Moscow State Med Univ, Moscow, Russia

[7] Hyogo Coll Med Hosp, Nishinomiya, Hyogo, Japan

[8] SP ZOZ Wojewodzki Szpital Zakazny Warszawie, Warsaw, Poland

[9] Asian Pacific Liver Ctr, Los Angeles, CA USA

[10] Gilead Sci Inc, Foster City, CA USA

[11] Natl Taiwan Univ, Taipei, Taiwan

[12] Azienda Osped Univ Pisana, UO Epatol, Pisa, Italy

[13] Hosp Univ Vall dHebron, Barcelona, Spain

来源：

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2018年 / 33卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：42 / 43

页数：2

共 50 条

[31] Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide
Hong, Hyeyeon
Choi, Won-Mook
Lee, Danbi
Shim, Ju Hyun
Kim, Kang Mo
Lim, Young-Suk
Lee, Han Chu
Choi, Jonggi
CLINICAL AND MOLECULAR HEPATOLOGY, 2024, 30 (01) : 49 - 63
[32] A phase 3 study comparing switching from tenofovir disoproxil fumarate to tenofovir alafenamide with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): week 48 efficacy and safety results
Lampertico, Pietro
Buti, Maria
Fung, Scott
Ahn, Sang Hoon
Chuang, Wan-Long
Ramji, Alnoor
Tak, Won Young
Chen, Chiyi
Tam, Edward
Bae, Ho
Ma, Xiaoli
Flaherty, John F.
Gaggar, Anuj
Lau, Audrey
Feierbach, Becket
Wu, George
Suri, Vithika
Subramanian, Mani
Trinh, Huy N.
Yoon, Seung Kew
Agarwal, Kosh
Lim, Young-Suk
Chan, Henry
JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E470 - E471
[33] Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment-naive patients with chronic hepatitis B
Lim, Jihye
Choi, Won-Mook
Shim, Ju Hyun
Lee, Danbi
Kim, Kang Mo
Lim, Young-Suk
Lee, Han Chu
Choi, Jonggi
JOURNAL OF HEPATOLOGY, 2022, 77 : S842 - S842
[34] Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patient with chronic hepatitis B
Nam, Heechul
Han, Ji Won
Lee, Soon Kyu
Yang, Hyun
Lee, Hae Lim
Sung, Pil Soo
Song, Myeong Jun
Kwon, Jung Hyun
Jang, Jeong Won
Chang, U-Im
Kim, Chang Wook
Nam, Soon Woo
Bae, Si Hyun
Choi, Jong Young
Yoon, Seung Kew
Yang, Jin Mo
Kim, Hee Yeon
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 (08) : 1673 - 1683
[35] A phase 3 study of tenofovir alafenamide (TAF) compared with tenofovir disoproxil fumarate (TDF) in patients with HBeAg-negative, chronic hepatitis B (CHB): Week 48 efficacy and safety results
Cheng, W.
Pianko, S.
Thompson, A.
Buti, M.
Gane, E.
Seto, W. K.
Chan, H. L. Y.
Chuang, W-L
Stepanova, T.
Hui, A-J
Lim, Y-S
Mehta, R.
Janssen, H.
Acharya, S. K.
Flaherty, J. F.
Massetto, B.
Cathcart, A.
Dinh, P.
Subramanian, G. M.
Mchutchison, J. G.
Pan, C.
Brunetto, M.
Izumi, N.
Marcellin, P.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 : 68 - 69
[36] Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment-naive chronic hepatitis B
Lim, Jihye
Choi, Won-Mook
Shim, Ju Hyun
Lee, Danbi
Kim, Kang Mo
Lim, Young-Suk
Lee, Han Chu
Choi, Jonggi
LIVER INTERNATIONAL, 2022, 42 (07) : 1517 - 1527
[37] Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B
Suzuki, Kazuharu
Suda, Goki
Yamamoto, Yoshiya
Abiko, Satoshi
Kinoshita, Kenji
Miyamoto, Shuichi
Sugiura, Ryo
Kimura, Megumi
Maehara, Osamu
Yamada, Ren
Kitagataya, Takashi
Shigesawa, Taku
Ohara, Masatsugu
Kawagishi, Naoki
Nakai, Masato
Sho, Takuya
Natsuizaka, Mitsuteru
Morikawa, Kenichi
Ogawa, Koji
Sakamoto, Naoya
PLOS ONE, 2022, 17 (01):
[38] Switching from efavirenz/emtricitabine/tenofovir (EFV/FTC/TDF) or rilpivirine/emtricitabine/tenofovir disoproxil fumarate (RPV/FTC/TDF) to rilpivirine/emtricitabine/tenofovir alafenamide (RPV/FTC/TAF): safety and efficacy through 48 weeks
Orkin, C.
DeJesus, E.
Ramgopal, M.
Crofoot, G.
Ruane, P.
LaMarca, A.
Mills, A.
Van der Cam, B.
De Wet, J.
Rockstroh, J.
Lazzarin, A.
Rijnders, B.
Podzamczer, D.
Thalme, A.
Stoeckle, M.
Chu, H.
Porter, D.
Liu, H.
Cheng, A.
Quirk, E.
SenGupta, D.
Cao, H.
HIV MEDICINE, 2017, 18 : 21 - 21
[39] A phase 3 study comparing tenofovir alafenamide (TAF) to tenofovir disoproxil fumarate (TDF) in patients with HBeAg-positive, chronic hepatitis B (CHB): efficacy and safety results at week 96
Agarwal, K.
Fung, S.
Seto, W. K.
Lim, Y. S.
Gane, E.
Janssen, H. L.
Sharma, M.
Chuang, W. L.
Bae, H.
Yoon, K. T.
Flaherty, J. F.
Lau, A.
Gaggar, A.
Suri, V.
Cathcart, A.
Lin, L.
Subramanian, G. M.
Shalimar
Furusyo, N.
Buti, M.
Chan, H. L.
JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S478 - S478
[40] 96-WEEK EFFICACY AND SAFETY OF TENOFOVIR DISOPROXIL FUMARATE (TDF) TO TENOFOVIR ALAFENAMIDE (TAF) SWITCH VS. CONTINUED TDF TREATMENT AMONG VIROLOGICALLY-SUPPRESSED HEPATITIS B PATIENTS OF ASIAN ETHNICITY
Ahn, Sang Hoon
Kao, Jia-Horng
Lampertico, Pietro
Ramji, Alnoor
Fung, Scott
Chuang, Wan-Long
Kim, Yoon Jun
Chen, Chi-Yi
Tam, Edward
Bae, Ho
Ma, Xiaoli
Lee, June Sung
Chan, Carol Yee Kwan
Yee, Leland J.
Sethi, Shalini
Flaherty, John
Zhao, Yang
Gaggar, Anuj
Hann, Hie Won
Lim, Young-Suk
Chan, Henry Lik Yuen
GUT, 2021, 70 : A77 - A78

← 1 2 3 4 5 →